September's Top 5 Infectious Disease Stories
Catch up on Contagion's top stories from the month of September.
As Fall officially began, respiratory viruses took center stage this month.
Our top stories this month focused on COVID-19, its treatments, and its complications. Paxlovid continued to be one of the most buzzed-about topics, as intrigue seems to follow this nirmatrelvir/ritonavir COVID-19 treatment.
Read all about it in this review of Contagion’s most-clicked articles in September.
1.
Mucosal Antibody Response to COVID-19 mRNA Vaccines Depends on Prior Infection
Injected COVID-19 mRNA vaccines alone were ineffective at producing mucosal antibody responses, according to a recent study that suggested seeking new strategies such as intranasal vaccines.
2.
Rebound of COVID-19 After Treatment With Paxlovid
COVID-19 viral load rebound occurred in 2.3% of nirmatrelvir–ritonavir (Paxlovid) recipients and in 1.7% of placebo recipients.
3.
Risk of Blood Clots Remains for Nearly a Year After COVID-19 Infection
In 2020 alone, the COVID-19 pandemic may have caused an additional 10500 heart attacks, strokes, and other blood clot complications across England and Wales.
4.
Paxlovid Prescribing by Pharmacists: A New Paradigm
The Paxlovid approval reaffirms the importance of pharmacists in fighting COVID-19.
5.
Here is a review of using this therapy in an immunocompromised patient population.
